Search

Your search keyword '"Ferrazzano A"' showing total 8 results
Start Over Author "Ferrazzano A" Journal journal of neurology
8 results on '"Ferrazzano A"'

1. Functional motor phenotypes: to lump or to split?

Author

Tinazzi, Michele, Geroin, Christian, Marcuzzo, Enrico, Cuoco, Sofia, Ceravolo, Roberto, Mazzucchi, Sonia, Pilotto, Andrea, Padovani, Alessandro, Romito, Luigi Michele, Eleopra, Roberto, Zappia, Mario, Nicoletti, Alessandra, Dallocchio, Carlo, Arbasino, Carla, Bono, Francesco, Magro, Giuseppe, Demartini, Benedetta, Gambini, Orsola, Modugno, Nicola, Olivola, Enrica, Bonanni, Laura, Zanolin, Elisabetta, Albanese, Alberto, Ferrazzano, Gina, De Micco, Rosa, Lopiano, Leonardo, Calandra-Buonaura, Giovanna, Petracca, Martina, Esposito, Marcello, Pisani, Antonio, Manganotti, Paolo, Tesolin, Lucia, Teatini, Francesco, Ercoli, Tommaso, Morgante, Francesca, and Erro, Roberto

Published
2021
Full Text
View/download PDF

4. Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study.

Author

Filippi, Massimo, Grimaldi, Luigi, Conte, Antonella, Totaro, Rocco, Valente, Maria Rosaria, Malucchi, Simona, Granella, Franco, Cordioli, Cinzia, Brescia Morra, Vincenzo, Zanetta, Chiara, Perini, Daria, Santoni, Laura, the EASIER Study Working Group, Ziccone, V., Garba, R., Motta, A., Albanesi, S., Oddo, O., Impagliato, A., and Ferrazzano, G.

Subjects
NATALIZUMAB, MULTIPLE sclerosis, TRAVEL time (Traffic engineering), DISEASE relapse, COST control
Abstract

Introduction: EASIER is a multicenter, observational, cross-sectional study investigating the consumption of healthcare resources, including healthcare professional (HCP) active working time, the costs associated with the current natalizumab intravenous (IV) administration, and the potential impact of the adoption of subcutaneous (SC) route. Methods: The EASIER study has three parts: (1) time and motion study to measure healthcare resources and working time needed for natalizumab IV administration using a digital data collection tool operated directly by HCPs; (2) HCP structured questionnaire-based estimation of the potential impact of natalizumab SC vs. IV administration; and (3) patient survey on the burden of natalizumab administration. Results: Nine Italian multiple sclerosis (MS) centers measured 404 IV natalizumab administration procedures and administered 26 HCP questionnaires and 297 patient questionnaires. Patients had a mean of 52 (range 1–176) previous IV administrations and spent a mean (median, IQR) of 152 (130, 94–184) minutes in the center per each IV procedure, with IV infusion covering 50% of the total. Including patient travel time, an average of 5 h was dedicated to each IV administration. Active working time by HCP amounted to 29 min per IV administration procedure, 70% of which by nursing staff. With adoption of the SC route, HCPs estimated a 50% reduction in patient procedure time and 55% lower HCP active working time. This translated into a 63% cost reduction for the MS center per natalizumab administration procedure. Conclusions: SC natalizumab administration will consistently reduce consumption of patient and HCP times per procedure and associated costs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

Author

D'Amico E., Zanghi A., Sciandra M., Lanzillo R., Callari G., Cortese A., Lus G., Lucchini M., Buccafusca M., Bonavita S., Gallo A., Curti E., Gajofatto A., Signoriello E., Bisecco A., Gobbin F., Ferro M. T., Ferrazzano G., Sparaco M., Valentino P., Mirabella M., Granella F., Bresciamorra V., Grimaldi L. M. E., Patti F., Borriello G., Grossi P., Carotenuto A., Siena E., Tsantes E., Giugno A., Abbadessa G. M., Chisari C. G., D'Amico, Emanuele, Zanghì, Aurora, Sciandra, Mariangela, Lanzillo, Roberta, Callari, Graziella, Cortese, Antonio, Lus, Giacomo, Lucchini, Matteo, Buccafusca, Maria, Bonavita, Simona, Gallo, Antonio, Curti, Erica, Gajofatto, Alberto, Signoriello, Elisabetta, Bisecco, Alvino, Gobbin, Francesca, Ferrò, Maria Teresa, Ferrazzano, Gina, Sparaco, Maddalena, Valentino, Paola, Mirabella, Massimiliano, Granella, Franco, Brescia Morra, Vincenzo, Grimaldi, Luigi Maria Edoardo, Patti, Francesco, D'Amico, E., Zanghi, A., Sciandra, M., Lanzillo, R., Callari, G., Cortese, A., Lus, G., Lucchini, M., Buccafusca, M., Bonavita, S., Gallo, A., Curti, E., Gajofatto, A., Signoriello, E., Bisecco, A., Gobbin, F., Ferro, M. T., Ferrazzano, G., Sparaco, M., Valentino, P., Mirabella, M., Granella, F., Bresciamorra, V., Grimaldi, L. M. E., Patti, F., Borriello, G., Grossi, P., Carotenuto, A., Siena, E., Tsantes, E., Giugno, A., Abbadessa, G. M., and Chisari, C. G.

Subjects
Adult, Data Analysis, Male, medicine.medical_specialty, Neurology, Efficacy, Toluidines, Dimethyl Fumarate, Hydroxybutyrates, Relapsing-Remitting, Multiple sclerosis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Multiple Sclerosis, Relapsing-Remitting, Internal medicine, Teriflunomide, Nitriles, medicine, Humans, Multiple sclerosi, 030212 general & internal medicine, Neuroradiology, Dimethyl fumarate, Proportional hazards model, business.industry, Safety, Female, Italy, Middle Aged, Crotonates, Immunosuppressive Agents, medicine.disease, Settore MED/26 - NEUROLOGIA, Event data, chemistry, Cohort, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

Background: The introduction of oral disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment. Objectives: To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients. Materials and Methods: Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were “time-to-first-relapse”, “time-to-Magnetic-Resonance-Imaging (MRI)-activity” and “time-to-disability-progression”. Results: 1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2years), with a predominance of men and higher level of disability (p < 0.001 for all). Patients on DMF had a higher number of relapses and radiological activity (p 38DMF = 3.83, CI = 1.11 to 13.23, p = 0.033). Both DMTs controlled similarly MRI activity and disability progression. Conclusions: Patients on DMF had higher relapse-free survival time than TRF group after the first 38 months ontherapy.

Published
2020

8. Motor and non-motor symptoms in blepharospasm: clinical and pathophysiological implications

Author

Giovanni Defazio, Alfredo Berardelli, Daniele Belvisi, Gina Ferrazzano, Isabella Berardelli, Viola Baione, Cristina Concolato, Giovanni Fabbrini, and Antonella Conte

Subjects
Male, Sleep Wake Disorders, Pediatrics, medicine.medical_specialty, Neurology, Eye Diseases, Blepharospasm, cognitive, 03 medical and health sciences, 0302 clinical medicine, Rating scale, blepharospasm, depression, dystonia, non-motor symptoms, medicine, Humans, Cognitive Dysfunction, 030212 general & internal medicine, Aged, Neuroradiology, Dystonia, Orbicularis oculi muscle, business.industry, Mental Disorders, Cognition, Middle Aged, medicine.disease, eye diseases, Pathophysiology, Female, Neurology (clinical), medicine.symptom, business, 030217 neurology & neurosurgery
Abstract

Patients with blepharospasm in addition to involuntary contraction of the orbicularis oculi muscle also have non-motor symptoms (psychiatric, sleep, cognitive, and ocular). In this paper, we investigated the relationship of non-motor with motor symptoms and the total burden of non-motor symptoms in patients with blepharospasm. Results were compared with those of age- and sex-matched healthy controls. We enrolled 60 patients with blepharospasm and 40 age-matched healthy controls. In all patients, the severity of blepharospasm was assessed clinically with the Blepharospasm Severity Rating Scale. All the participants underwent a psychiatric, sleep, cognitive, and ocular symptom evaluation. We investigated the correlations between motor, non-motor symptoms, and patients’ clinical and demographic features. The frequency of psychiatric, sleep, and cognitive disorders and ocular symptoms was higher in blepharospasm patients than in healthy controls. Non-motor symptoms coexisted in the majority of patients and there was no correlation between non-motor and motor symptoms. The total burden of non-motor symptoms did not associate with motor symptoms and demographic features in blepharospasm. Non-motor symptoms are independent of motor features and likely belong to the clinical spectrum of blepharospasm. The presence of non-motor symptoms possibly reflects a complex network disorder of blepharospasm.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results